FDA Approval of Adjuvant Pembrolizumab for NSCLC | IASLC
On January 26, 2023, the US FDA granted approval for pembrolizumab, an anti-PD-1 antibody, as adjuvant therapy for patients with resected NSCLC. In this episode …
On January 26, 2023, the US FDA granted approval for pembrolizumab, an anti-PD-1 antibody, as adjuvant therapy for patients with resected NSCLC. In this episode …
The CT Screening Symposium is a 1-day, immersive, in-person event being featured at WCLC 2024 focused on lung cancer screening technologies and best practices. …
The National Cancer Plan provides a comprehensive framework for meaningful collaboration to change how we know cancer today.
No files in this folder. Sign in to add files to this
Dr. Narjust Florez, Lung Cancer Considered Host, encourages members to participate in the first IASLC Global Membership Survey on Inclusivity. The 5-minute survey, is available…
No files in this folder. Sign in to add files to this
In the wake of the FDA’s approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomo …
The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and…
The association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to…
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of…
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable…